发布求助
文献互助 智能选刊 最新文献

Immuno-oncology technology最新文献

筛选
英文 中文
Title Page
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/S2590-0188(24)00315-0
{"title":"Title Page","authors":"","doi":"10.1016/S2590-0188(24)00315-0","DOIUrl":"10.1016/S2590-0188(24)00315-0","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 101018"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143177785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ESMO
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/S2590-0188(24)00316-2
{"title":"ESMO","authors":"","doi":"10.1016/S2590-0188(24)00316-2","DOIUrl":"10.1016/S2590-0188(24)00316-2","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 101019"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143177787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
1O Exploration of gut microbiota biomarkers in treatment-naïve advanced NSCLC patients undergoing chemo-immunotherapy: Insights from the phase III trial, JCOG2007 (NIPPON)
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100885
T. Hakozaki , K. Tanaka , Y. Shiraishi , Y. Sekino , N. Mitome , Y. Okuma , T. Aiba , T. Utsumi , J. Tanizaki , K. Azuma , S. Hara , R. Morita , S. Niho , T. Yokoyama , R. Toyozawa , H. Horinouchi , I. Okamoto , Y. Hosomi , Y. Ohe
{"title":"1O Exploration of gut microbiota biomarkers in treatment-naïve advanced NSCLC patients undergoing chemo-immunotherapy: Insights from the phase III trial, JCOG2007 (NIPPON)","authors":"T. Hakozaki , K. Tanaka , Y. Shiraishi , Y. Sekino , N. Mitome , Y. Okuma , T. Aiba , T. Utsumi , J. Tanizaki , K. Azuma , S. Hara , R. Morita , S. Niho , T. Yokoyama , R. Toyozawa , H. Horinouchi , I. Okamoto , Y. Hosomi , Y. Ohe","doi":"10.1016/j.iotech.2024.100885","DOIUrl":"10.1016/j.iotech.2024.100885","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100885"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143177797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changes in AXL and/or MITF melanoma subpopulations in patients receiving immunotherapy 接受免疫治疗的患者AXL和/或MITF黑色素瘤亚群的变化
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.101009
M. Willemsen , J. Bulgarelli , S.K. Chauhan , R.R. Lereim , D. Angeli , G. Grisendi , G. Krebbers , I. Davidson , J.A. Kyte , M. Guidoboni , R.M. Luiten , W.J. Bakker
{"title":"Changes in AXL and/or MITF melanoma subpopulations in patients receiving immunotherapy","authors":"M. Willemsen ,&nbsp;J. Bulgarelli ,&nbsp;S.K. Chauhan ,&nbsp;R.R. Lereim ,&nbsp;D. Angeli ,&nbsp;G. Grisendi ,&nbsp;G. Krebbers ,&nbsp;I. Davidson ,&nbsp;J.A. Kyte ,&nbsp;M. Guidoboni ,&nbsp;R.M. Luiten ,&nbsp;W.J. Bakker","doi":"10.1016/j.iotech.2024.101009","DOIUrl":"10.1016/j.iotech.2024.101009","url":null,"abstract":"<div><h3>Background</h3><div>Tumor heterogeneity is a hurdle to effective therapy, as illustrated by the ‘mixed responses’ frequently seen in immunotherapy-treated patients. Previously, AXL+ tumor cells were identified to be highly resistant to targeted therapy, whereas more differentiated MITF+ tumor cells do respond to RAF and MEK inhibitors.</div></div><div><h3>Patients and methods</h3><div>In this study, we analyzed tumor heterogeneity and explored the presence of the previously described AXL+ or MITF+ melanoma subpopulations in metastatic tissues by NanoString gene expression analysis, single-cell RNA sequencing and <em>in situ</em> multiplex immunofluorescence. Furthermore, we analyzed how these subpopulations correlate with immunological pressure and response to immunotherapy by immunomodulating antibodies or autologous tumor lysate-loaded dendritic cell vaccination.</div></div><div><h3>Results</h3><div>Our data demonstrate large interpatient variability and variable therapy-induced changes independent of the type of therapy. We identify the presence of previously described AXL+ and MITF+ subpopulations in metastatic tissues both at the mRNA level and <em>in situ</em> at the protein level, and demonstrate that MITF+ melanoma cells are significantly decreased upon immunotherapy, while AXL+ melanoma cell numbers are stable. MITF+ tumor cells showed the most significant inverse correlation with CD8+ T cells. Our patient cohort also shows that immunotherapy-induced changes in the abundance of AXL+ or MITF+ tumor cells did not correlate with improved survival.</div></div><div><h3>Conclusions</h3><div>Overall, this study suggests that more differentiated MITF+ tumors are efficiently targeted by immunotherapy, while AXL+ tumor cells may be more resistant, analogous to their response to targeted therapy.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 101009"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142759750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
55P Engineering of chimeric cytokine receptors (CCR) to induce IL-7 signaling to CAR-T cells for solid tumor treatment
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100866
M. Soria-Castellano, S. Colell, T. Lobo-Jarne, C.A. Di Trani, M. Giménez-Alejandre, P. Barbao, I. Andreu-Saumell, H. Calderon, J. Castellsagué, A. Rodriguez Garcia, S. Guedan
{"title":"55P Engineering of chimeric cytokine receptors (CCR) to induce IL-7 signaling to CAR-T cells for solid tumor treatment","authors":"M. Soria-Castellano,&nbsp;S. Colell,&nbsp;T. Lobo-Jarne,&nbsp;C.A. Di Trani,&nbsp;M. Giménez-Alejandre,&nbsp;P. Barbao,&nbsp;I. Andreu-Saumell,&nbsp;H. Calderon,&nbsp;J. Castellsagué,&nbsp;A. Rodriguez Garcia,&nbsp;S. Guedan","doi":"10.1016/j.iotech.2024.100866","DOIUrl":"10.1016/j.iotech.2024.100866","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100866"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143177300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
80P Tumor markers evolution in pts treated with TCE and association with radiologic response
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100823
C. d'Abrigeon , K. Ouali , N. Herbel , S. Champiat , A. Hollebecque , C. Smolenschi , M. Sakkal , R. Bahleda , A. Gazzah , A. Patrikidou , J-M. Michot , T. Hueso , S. Ammari , Y. Loriot , C.P. Massard , A. Bernard-Tessier , M. Texier , C. Baldini
{"title":"80P Tumor markers evolution in pts treated with TCE and association with radiologic response","authors":"C. d'Abrigeon ,&nbsp;K. Ouali ,&nbsp;N. Herbel ,&nbsp;S. Champiat ,&nbsp;A. Hollebecque ,&nbsp;C. Smolenschi ,&nbsp;M. Sakkal ,&nbsp;R. Bahleda ,&nbsp;A. Gazzah ,&nbsp;A. Patrikidou ,&nbsp;J-M. Michot ,&nbsp;T. Hueso ,&nbsp;S. Ammari ,&nbsp;Y. Loriot ,&nbsp;C.P. Massard ,&nbsp;A. Bernard-Tessier ,&nbsp;M. Texier ,&nbsp;C. Baldini","doi":"10.1016/j.iotech.2024.100823","DOIUrl":"10.1016/j.iotech.2024.100823","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100823"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143177308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
70P Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small cell lung cancer
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100813
H. Wang , L. Cheng , Q. Wang , C. Zhou
{"title":"70P Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small cell lung cancer","authors":"H. Wang ,&nbsp;L. Cheng ,&nbsp;Q. Wang ,&nbsp;C. Zhou","doi":"10.1016/j.iotech.2024.100813","DOIUrl":"10.1016/j.iotech.2024.100813","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100813"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143127802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
71P Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients: A systematic review and meta-analysis
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100814
K. Lallas , E. Chatziioannou , D. Durak , G. Frey , L.M. Serna Higuita , M-L. Rasch , A. Kyrgidis , Z. Apalla , U. Leiter-Stoppke , L. Flatz , A. Lallas , T.M.S. Amaral
{"title":"71P Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients: A systematic review and meta-analysis","authors":"K. Lallas ,&nbsp;E. Chatziioannou ,&nbsp;D. Durak ,&nbsp;G. Frey ,&nbsp;L.M. Serna Higuita ,&nbsp;M-L. Rasch ,&nbsp;A. Kyrgidis ,&nbsp;Z. Apalla ,&nbsp;U. Leiter-Stoppke ,&nbsp;L. Flatz ,&nbsp;A. Lallas ,&nbsp;T.M.S. Amaral","doi":"10.1016/j.iotech.2024.100814","DOIUrl":"10.1016/j.iotech.2024.100814","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100814"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143127803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
60P Innovative applications of neoantigens in dendritic cell-derived exosome (DEX) therapy and their impact on personalized cancer treatment
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100871
R.E. Gutierrez , F. Gutierrez Castro , I. Rivadeneira , F. Krakowiak , J. Iturra , W. Dorado , R. Aguilera
{"title":"60P Innovative applications of neoantigens in dendritic cell-derived exosome (DEX) therapy and their impact on personalized cancer treatment","authors":"R.E. Gutierrez ,&nbsp;F. Gutierrez Castro ,&nbsp;I. Rivadeneira ,&nbsp;F. Krakowiak ,&nbsp;J. Iturra ,&nbsp;W. Dorado ,&nbsp;R. Aguilera","doi":"10.1016/j.iotech.2024.100871","DOIUrl":"10.1016/j.iotech.2024.100871","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100871"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143128725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
87P Access to vedolizumab for the management of immune-related colitis (IRC): A United Kingdom study
Immuno-oncology technology Pub Date : 2024-12-01 DOI: 10.1016/j.iotech.2024.100830
F. Coe , M. Deisai , K. Kantilal , J. Parkes , K. Paterson , A. Tew
{"title":"87P Access to vedolizumab for the management of immune-related colitis (IRC): A United Kingdom study","authors":"F. Coe ,&nbsp;M. Deisai ,&nbsp;K. Kantilal ,&nbsp;J. Parkes ,&nbsp;K. Paterson ,&nbsp;A. Tew","doi":"10.1016/j.iotech.2024.100830","DOIUrl":"10.1016/j.iotech.2024.100830","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100830"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143129138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信